A Study of Ziresovir (AK0529) in High-risk Adult With Respiratory Syncytial Virus (RSV) Infection.

NCT07658534 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

290

Enrollment

INDUSTRY

Sponsor class

Conditions

Respiratory Syncytial Virus Infections

Interventions

DRUG: Ziresovir (AK0529)
DRUG: Placebo

Sponsor

Shanghai Ark Biopharmaceutical Co., Ltd.